​In the human body, so-called dendritic cells are responsible for activating our immune system. While researchers previously believed that tumors could repress these dendritic cells – blocking an adequate natural cancer defense mechanism – a new study has painted a more positive picture. A team led by prof. Jo Van Ginderachter (VIB-Vrije Universiteit Brussel) revealed that two immune response-stimulating dendritic cell types do exist within tumors. The scientists were able to isolate these cells and use them to “vaccinate” tumors, slowing tumor growth. This success could lead to innovative new cancer immunotherapies. The results of the study are published in the high-impact journal Nature Communications.

Following successful trials demonstrating bioequivalence to Nuvaring, Mithra Pharmaceuticals sets in motion the next steps to bring its Myring to the market.

Aratana Therapeutics, a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, won Animal Pharm's Best Company in North America 2016.

MDxHealth Announces Horizon Blue Cross Blue Shield of New Jersey Issues Positive Coverage Policy on ConfirmMDx. The decision provides access to more than 3.8 million members.

PharmaFluidics NV, a game-changing innovator in the field of analytical chromatography, announced today that it has raised 2.7 million euro of additional funding.